Powered by

-SAB Capra awarded $ 225K from NIH to broaden novel immunotherapy platform

Feb 05, 2018 - ENP Newswire

Sioux Falls - SAB Capra, LLC, a privately-held, emerging bioscience company developing targeted human polyclonal antibodies for use in diagnostics, testing and immunotherapeutics, has been awarded a $ 225,000 grant from the National Institutes of Health (NIH) to advance its novel immunotherapy platform targeting pandemic influenza in collaboration with Utah State University.

The company will use the funds, awarded through the National Institute of Allergy and Infectious Disease (NIAID), to...